TY  - JOUR
AU  - Chaparro, Maria
AU  - Donday, Maria G.
AU  - Barreiro-de Acosta, Manuel
AU  - Domenech, Eugeni
AU  - Esteve, Maria
AU  - Garcia-Sanchez, Valle
AU  - Nos, Pilar
AU  - Panes, Julian
AU  - Martinez, Concepcion
AU  - Gisbert, Javier P.
AU  - EXIT Study Grp GETECCU
PY  - 2019
DO  - 10.1177/1756284819874202
SN  - 1756-283X
UR  - http://hdl.handle.net/10668/19102
T2  - Therapeutic advances in gastroenterology
AB  - Background: Patients with inflammatory bowel disease who achieve remission with anti-tumour necrosis factor (anti-TNF) drugs may have treatment withdrawn due to safety concerns and cost considerations, but there is a lack of prospective, controlled...
LA  - en
PB  - Sage publications ltd
KW  - anti-tumour necrosis factor
KW  - inflammatory bowel disease
KW  - withdrawal
KW  - Spanish work productivity
KW  - Anti-tnf discontinuation
KW  - Evidence-based consensus
KW  - Crohns-disease
KW  - Ulcerative-colitis
KW  - Relapse
KW  - Questionnaire
KW  - Validation
KW  - Therapy
KW  - Management
TI  - Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
TY  - research article
VL  - 12
ER  -